Marketable Securities

9 Months Ended

Mar. 31, 2018

Marketable Securities

Marketable Securities

3.          Marketable Securities

Immunomedics considers all of its current investments to be available-for-sale. Marketable securities at March 31, 2018 consisted of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized
	Cost		Gain		(Loss)		Fair Value
U.S. Treasury Bonds	$	14,109	$	—	$	(26)	$	14,083
Certificate of Deposits		8,371		—		—		8,371
U.S. Government Sponsored Agencies		10,882		—		(10)		10,872
Corporate Debt Securities		8,380		—		(20)		8,360
Commercial Paper		10,368		—		(8)		10,360
	$	52,110	$	—	$	(64)	$	52,046

Maturities of debt securities classified as available-for-sale were as follows at March 31, 2018 (in thousands):

			Net Carrying
	Fair Value		Amount
Due within one year	$	47,046	$	47,286
Due after one year through five years		5,000		5,000
	$	52,046	$	52,286

Marketable securities at June 30, 2017 consisted of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized
	Cost		Gain		(Loss)		Fair Value
U.S. Treasury Bonds	$	35,086	$	—	$	(24)	$	35,062
Certificate of Deposits		15,298		—		—		15,298
U.S. Government Sponsored Agencies		18,357		—		(13)		18,344
Corporate Debt Securities		32,692		—		(33)		32,659
Commercial Paper		10,144		1		—		10,145
	$	111,577	$	1	$	(70)	$	111,508

Maturities of debt securities classified as available-for-sale were as follows at June 30, 2017 (in thousands):

			Net Carrying
	Fair Value		Amount
Due within one year	$	89,477	$	89,728
Due after one year through five years		22,031		22,149
	$	111,508	$	111,877